Trial Profile

Phase I clinical study of 6B11 anti-idiotypic miniantibody-loaded dendritic cells and cytokine-induced autologous ovarian cancer killer cell injection (6B11-OCIK injection) in the treatment of drug-resistant recurrent ovarian cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Oct 2023 As at the date of this interim report, the Company has completed the enrollment of six targeted patients. The Company intends to complete the enrollment of targeted patients and publish the preliminary analysis and results in 2023.
26 Oct 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com